Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 661-670

  Venkatesh, Prasanna K ^a   Pattillo, Christopher B ^a   Branch, Billy ^a   Hood, Jay ^a   Thoma, Steven ^a   Illum, Sandra ^a   Pardue, Sibile ^a   Teng, Xinjun ^b   Patel, Rakesh P ^b   Kevil, Christopher G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angiogenesis; Blood flow; ENOS; Ischaemia; Nitric oxide; Nitrite

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY LIGATION; ARTERY PERFUSION; ARTICLE; BLOOD; BLOOD FLOW; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME SYNTHESIS; FEMORAL ARTERY; HINDLIMB ISCHEMIA; LASER DOPPLER FLOWMETRY; LEG ISCHEMIA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE PERFUSION;

ANIMALS; CELL DIVISION; CHRONIC DISEASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HINDLIMB; ISCHEMIA; LASER-DOPPLER FLOWMETRY; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS;

EID: 76749112482     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq002     Document Type: Article

References (48)

1. Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol 2002;13:7-11.
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324.
4. Higashi Y, Nishioka K, Umemura T, Chayama K, Yoshizumi M. Oxidative stress, endo-thelial function and angiogenesis induced by cell therapy and gene therapy. Curr Pharm Biotechnol 2006;7:109-116.
5. Lekas M, Lekas P, Latter DA, Kutryk MB, Stewart DJ. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006;21:376-384.
6. Lombardi F, Rambaldi R. Coronary angiogenesis: dipyridamole is back on the stage? Eur Heart J 2001;22:1151-1153.
7. Mannava K, Money SR. Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions. Am J Cardiovasc Drugs 2007;7: 59-66.
8. Contreras D, Robles H, Romo E, Rios A, Escalante B. The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 2006;112:553-563.
9. Cooke JP. NO and angiogenesis. Atheroscler Suppl 2003;4:53-60.
10. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 2005;102:10999-11004.
11. Kumar D, Branch BG, Pattillo CB, Hood J, Thoma S, Simpson S et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA 2008;105:7540-7545.
12. Adair TH. Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol 2005;289:R283-R296.
13. Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 2002;55:520-525.
14. Lankford AR, Yang JN, Rose'Meyer R, French BA, Matherne GP, Fredholm BB et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2006;290:H1469-H1473.
15. Senthilkumar A, Smith RD, Khitha J, Arora N, Veerareddy S, Langston W et al. Silde-nafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol 2007;27:1947-1954.
16. Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G et al. Pharmacokinetics of oral dipyridamole and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982;23:229-234.
17. Isbell TS, Sun CW, Wu LC, Teng X, Vitturi DA, Branch BG et al. SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation. Nat Med 2008;14: 773-777.
18. Kevil CG, Orr AW, Langston W, Mickett K, Murphy-Ullrich J, Patel RP et al. Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. J Biol Chem 2004;279:19230-19238.
19. Langston W, Chidlow JH Jr, Booth BA, Barlow SC, Lefer DJ, Patel RP et al. Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radic Biol Med 2007;42:720-729.
20. Bult H, Fret HR, Jordaens FH, Herman AG. Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost 1991;66:343-349.
21. Kim HH, Sawada N, Soydan G, Lee HS, Zhou Z, Hwang SK et al. Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab 2008;28:1285-1293.
22. Lepore JJ, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant 2005;24:1950-1956.
23. Elrod JW, Calvert JW, Gundewar S, Bryan NS, Lefer DJ. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA 2008;105:11430-11435.
24. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
25. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308: 81-106.
26. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR Jr et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984;310:209-214.
27. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134.
28. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous translum-inal coronary angioplasty. N Engl J Med 1998;318:1714-1719.
29. Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971;284:1391-1394.
30. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arter-iographically controlled trial. Lancet 1985;1:415-419.
31. Picano E, Michelassi C. Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc Res 1997;33:666-670.
32. Symons JD, Firoozmand E, Longhurst JC. Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise. A role for adenosine. Circ Res 1993;73:503-513.
33. Tornling G, Unge G, Skoog L, Ljungqvist A, Carlsson S, Adolfsson J. Proliferative activity of myocardial capillary wall cells in dipyridamole-treated rats. Cardiovasc Res 1978;12:692-695.
34. Tornling G, Adolfsson J, Unge G, Ljungqvist A. Capillary neoformation in skeletal muscle of dipyridamole-treated rats. Arzneimittelforschung 1980;30:791-792.
35. Tornling G, Unge G, Adolfsson J, Ljungqvist A, Carlsson S. Proliferative activity of capillary wall cells in skeletal muscle of rats during long-term treatment with dipyri-damole. Arzneimittelforschung 1980;30:622-623.
36. Ziada AM, Hudlicka O, Tyler KR, Wright AJ. The effect of long-term vasodilatation on capillary growth and performance in rabbit heart and skeletal muscle. Cardiovasc Res 1984;18:724-732.
37. Cui X, Chopp M, Zacharek A, Zhang C, Roberts C, Chen J. Role of endothelial nitric oxide sythetase in arteriogenesis after stroke in mice. Neuroscience 2009;159: 744-750.
38. Lloyd PG, Yang HT, Terjung RL. Arteriogenesis and angiogenesis in rat ischemic hind-limb: role of nitric oxide. Am J Physiol-Heart Circ 2001;281:H2528-H2538.
39. Mees B, Wagner S, Ninci E, Tribulova S, Martin S, van Haperen R et al. Endothelial nitric oxide synthase activity is essential for vasodilation during blood flow recovery but not for arteriogenesis. Arterioscler Thromb Vasc Biol 2007;27: 1926-1933.
40. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Cardiac fibroblasts express the cAMP-adenosine pathway. Hypertension 2000;36:337-342.
41. Glombitza S, Dragon S, Berghammer M, Pannermayr M, Baumann R. Adenosine causes cAMP-dependent activation of chick embryo red cell carbonic anhydrase and 2,3-DPG synthesis. Am J Physiol 1996;271:R973-R981.
42. Kadatz R, Diederen W. The influence of coronary-active drugs on the circulation and oxygen tension of the myocardium in experimental coronary insufficiency. Arztl Forsch 1967;21:51-60.
43. Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 1981;21:9-15.
44. Gladwin MT, Raat NJ, Shiva S, Dezfulian C, Hogg N, Kim-Shapiro DB et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol 2006;291: H2026-H2035.
45. Li J, Fenton RA, Wheeler HB, Powell CC, Peyton BD, Cutler BS et al. Adenosine A2a receptors increase arterial endothelial cell nitric oxide. J Surg Res 1998;80:357-364.
46. Li JM, Fenton RA, Cutler BS, Dobson JG Jr. Adenosine enhances nitric oxide production by vascular endothelial cells. Am J Physiol 1995;269:C519-C523.
47. Olanrewaju HA, Mustafa SJ. Adenosine A(2A) and A(2B) receptors mediated nitric oxide production in coronary artery endothelial cells. Gen Pharmacol 2000;35: 171-177.
48. Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 2005;65:803-812.